Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Thermo Fisher has outperformed the market with a 420%+ return over the past decade, but its current valuation is high. The company's recent results show mixed performance, with slight revenue decline, but improved earnings-per-share and raised 2024 guidance. Despite strong growth prospects and market tailwinds, the stock's high valuation and low dividend yield make it a hold for now.
One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).